| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Neuroimmunology Unit, Montreal Neurological Institute, Montreal, Quebec, Canada;
Departments of Oncology and Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada; and
School of Biological Sciences, University of East Anglia, Norwich, United Kingdom
Circulating B cells enter the CNS as part of normal immune surveillance and in pathologic states, including the common and disabling illness multiple sclerosis. However, little is known about the molecular mechanisms that mediate human B cell interaction with the specialized brain endothelial cells comprising the blood-brain barrier (BBB). We studied the molecular mechanisms that regulate the migration of normal human B cells purified ex vivo, across human adult brain-derived endothelial cells (HBECs). We found that B cells migrated across HBECs more efficiently than T cells from the same individuals. B cell migration was significantly inhibited by blocking Abs to the adhesion molecules ICAM-1 and VLA-4, but not VCAM-1, similar to the results previously reported for T cells. Blockade of the chemokines monocyte chemoattractant protein-1 and IL-8, but not RANTES or IFN-
-inducible protein-10, significantly inhibited B cell migration, and these results were correlated with the chemokine receptor expression of B cells measured by flow cytometry and by RNase protection assay. Tissue inhibitor of metalloproteinase-1, a natural inhibitor of matrix metalloproteinases, significantly decreased B cell migration across the HBECs. A comprehensive RT-PCR comparative analysis of all known matrix metalloproteinases and tissue inhibitors of metalloproteinases in human B and T cells revealed distinct profiles of expression of these molecules in the different cell subsets. Our results provide insights into the molecular mechanisms that underlie human B cell migration across the BBB. Furthermore, they identify potential common, and unique, therapeutic targets for limiting CNS B cell infiltration and predict how therapies currently developed to target T cell migration, such as anti-VLA-4 Abs, may impact on B cell trafficking.
This article has been cited by other articles:
|
|
 |
|
  T. Y. Poh, J. Pease, J. R. Young, N. Bumstead, and P. Kaiser Re-evaluation of Chicken CXCR1 Determines the True Gene Structure: CXCLi1 (K60) AND CXCLi2 (CAF/INTERLEUKIN-8) ARE LIGANDS FOR THIS RECEPTOR J. Biol. Chem., June 13, 2008; 283(24): 16408 - 16415. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Ifergan, H. Kebir, M. Bernard, K. Wosik, A. Dodelet-Devillers, R. Cayrol, N. Arbour, and A. Prat The blood-brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells Brain, March 1, 2008; 131(3): 785 - 799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Minagar, J. S. Alexander, R. N. Schwendimann, R. E. Kelley, E. Gonzalez-Toledo, J. J. Jimenez, L. Mauro, W. Jy, and S. J. Smith Combination Therapy With Interferon Beta-1a and Doxycycline in Multiple Sclerosis: An Open-Label Trial Arch Neurol, February 1, 2008; 65(2): 199 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Crocker, R. F. Frausto, J. K. Whitmire, N. Benning, R. Milner, and J. L. Whitton Amelioration of Coxsackievirus B3-Mediated Myocarditis by Inhibition of Tissue Inhibitors of Matrix Metalloproteinase-1 Am. J. Pathol., December 1, 2007; 171(6): 1762 - 1773. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Wosik, R. Cayrol, A. Dodelet-Devillers, F. Berthelet, M. Bernard, R. Moumdjian, A. Bouthillier, T. L. Reudelhuber, and A. Prat Angiotensin II Controls Occludin Function and Is Required for Blood Brain Barrier Maintenance: Relevance to Multiple Sclerosis J. Neurosci., August 22, 2007; 27(34): 9032 - 9042. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Smith, D. Choi, T. J. Chipps, Y. Pan, D. O. Zamora, M. H. Davies, B. Babra, M. R. Powers, S. R. Planck, and J. T. Rosenbaum Unique Gene Expression Profiles of Donor-Matched Human Retinal and Choroidal Vascular Endothelial Cells Invest. Ophthalmol. Vis. Sci., June 1, 2007; 48(6): 2676 - 2684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Duddy, M. Niino, F. Adatia, S. Hebert, M. Freedman, H. Atkins, H. J. Kim, and A. Bar-Or Distinct Effector Cytokine Profiles of Memory and Naive Human B Cell Subsets and Implication in Multiple Sclerosis J. Immunol., May 15, 2007; 178(10): 6092 - 6099. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Melamed, O. Messika, L. Glass-Marmor, and A. Miller Modulation of matrix metalloproteinase-9 (MMP-9) secretion in B lymphopoiesis Int. Immunol., September 1, 2006; 18(9): 1355 - 1362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Krumbholz, D. Theil, S. Cepok, B. Hemmer, P. Kivisakk, R. M. Ransohoff, M. Hofbauer, C. Farina, T. Derfuss, C. Hartle, et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment Brain, January 1, 2006; 129(1): 200 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Merlo, C. Tenca, F. Fais, L. Battini, E. Ciccone, C. E. Grossi, and D. Saverino Inhibitory Receptors CD85j, LAIR-1, and CD152 Down-Regulate Immunoglobulin and Cytokine Production by Human B Lymphocytes Clin. Vaccine Immunol., June 1, 2005; 12(6): 705 - 712. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Zhou, N. W. Marten, C. C. Bergmann, W. B. Macklin, D. R. Hinton, and S. A. Stohlman Expression of Matrix Metalloproteinases and Their Tissue Inhibitor during Viral Encephalitis J. Virol., April 15, 2005; 79(8): 4764 - 4773. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
